Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Merck
Colorcon
Moodys
Boehringer Ingelheim

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR AMOXIL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Amoxil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00377403 ↗ Treatment of Acute Sinusitis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 4 2006-10-01 This study will compare the symptom relief provided by 5 cold medicines versus the symptom relief provided by the same 5 cold medicines plus the antibiotic, amoxicillin, in people who have sinus infections. Treatment with amoxicillin may be more effective than treatment with cold medicines alone. Two hundred adult volunteers, aged 18 to 70 years old, with sinus infections will participate in this study for 28 days. Volunteers will receive a 10-day course of either amoxicillin or placebo (substance containing no medication). In addition, all volunteers will receive pain medication, a chest decongestant, nasal decongestants, and cough medicine as needed. Volunteers will be interviewed by telephone on days 0, 3, 7, 10, and 28 following the start of treatment. The study will look at quality of life factors such as change in functional status (ability to perform daily activities) and symptoms, recurrence of the infection, satisfaction with care, and the direct costs of treatment.
NCT00377403 ↗ Treatment of Acute Sinusitis Completed Washington University School of Medicine Phase 4 2006-10-01 This study will compare the symptom relief provided by 5 cold medicines versus the symptom relief provided by the same 5 cold medicines plus the antibiotic, amoxicillin, in people who have sinus infections. Treatment with amoxicillin may be more effective than treatment with cold medicines alone. Two hundred adult volunteers, aged 18 to 70 years old, with sinus infections will participate in this study for 28 days. Volunteers will receive a 10-day course of either amoxicillin or placebo (substance containing no medication). In addition, all volunteers will receive pain medication, a chest decongestant, nasal decongestants, and cough medicine as needed. Volunteers will be interviewed by telephone on days 0, 3, 7, 10, and 28 following the start of treatment. The study will look at quality of life factors such as change in functional status (ability to perform daily activities) and symptoms, recurrence of the infection, satisfaction with care, and the direct costs of treatment.
NCT00778050 ↗ Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions Completed Ranbaxy Laboratories Limited N/A 2002-10-01 This study compared the relative bioavailability (rate and extent of absorption) of amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited with that of Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals following single oral dose (600 mg) in healthy, adult, subjects under fasting conditions using a randomized two-way crossover design.
NCT01431989 ↗ Amoxicillin Bioequivalence Study Brazil - Fast Completed GlaxoSmithKline Phase 1 2011-05-27 This study is prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods. The volunteers received, in each period, the reference or the test formulation, according to the randomization list, under fasting conditions, in order to evaluate if the reference and test formulations are bioequivalent.
NCT01530009 ↗ The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children Active, not recruiting Nationwide Children's Hospital N/A 2012-01-01 The goal of this study is to determine whether amoxicillin (AMX) alone has an appreciable effect on upper gastrointestinal motility compared to placebo. In particular, induction of phase III of the interdigestive migrating motor complex (MMC) by AMX will be the primary outcome of the study. MMCs are periodic waves of electrical activity resulting in muscular contractions that pass through the walls of the stomach and intestinal tract during the fasting state. It is characterized by an initial period where there is a minimal electrical activity and muscular contraction (phase I), followed by a gradual increase in the frequency of contractions (phase III) that often leads to a characteristic cluster of contractions (phase III). This cycle occurs only in the fasting state in normal individuals and the frequency of phase III is quite varied, dependent on age and the presence of any underlying abnormalities in gastrointestinal motility. Secondary outcomes will include characteristics of the MMC, patient demographics in responders and non-responders, and the safety profile of AMX at the intervention dose.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amoxil

Condition Name

Condition Name for Amoxil
Intervention Trials
Community-acquired Pneumonia 3
Helicobacter Pylori Infection 2
Healthy 1
Acute Tonsillitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amoxil
Intervention Trials
Respiratory Tract Infections 3
Pneumonia 3
Periodontitis 2
Aggressive Periodontitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amoxil

Trials by Country

Trials by Country for Amoxil
Location Trials
Brazil 5
United States 4
Canada 3
Lebanon 1
Pakistan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amoxil
Location Trials
North Dakota 1
Missouri 1
New York 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amoxil

Clinical Trial Phase

Clinical Trial Phase for Amoxil
Clinical Trial Phase Trials
Phase 4 10
Phase 2/Phase 3 3
Phase 2 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amoxil
Clinical Trial Phase Trials
Completed 12
Withdrawn 2
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amoxil

Sponsor Name

Sponsor Name for Amoxil
Sponsor Trials
Washington University School of Medicine 2
Children's Hospital of Eastern Ontario 2
Hamilton Health Sciences Corporation 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amoxil
Sponsor Trials
Other 29
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Medtronic
Express Scripts
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.